Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390709 · ClinicalTrials.gov registry record
PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)
A clinical trial of Rheumatoid Arthritis, sponsored by Scipher Medicine.
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 1
- Study location
NCT06390709 is a study of Rheumatoid Arthritis that is actively recruiting participants, run by Scipher Medicine. The registered enrollment target is 1,100 participants, below the 4,685-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06390709, a study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Scipher Medicine.
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).
Conditions Studied
Interventions
- OTHER Lab Collection Only
Study Locations (1)
California
- Medvin Clinical Research//Amicus Arthritis - Whittier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06390709
The ClinicalTrials.gov registry entry for NCT06390709 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,685-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (77% lower). The listed sponsor is Scipher Medicine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Lab Collection Only is the first listed.
NCT06390709 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06390709 about?
NCT06390709 is a clinical study titled "PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)". Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 in...
What is the current status of trial NCT06390709?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2024-04-08. Estimated completion is 2025-12-31.
What conditions does trial NCT06390709 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06390709?
The interventions under investigation include: Lab Collection Only (OTHER).
Who is sponsoring clinical trial NCT06390709?
This trial is sponsored by Scipher Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390709 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.